TONIGHT! Join in as Kyle Dennis, 27 year-old,
self-made millionaire, reveals his newest trading strategy.
self-made millionaire, reveals his newest trading strategy.
Days
Hours
Minutes
Seconds
Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
Be 'active' in the market while NOT being tied to your desk.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| CELG | Celgene Corporation | -1.14% | 78.63 | 1.2% | $618.81m | |
| AMGN | Amgen Inc. | 0.16% | 178.24 | 1.2% | $557.24m | |
| GILD | Gilead Sciences, Inc. | -0.22% | 67.38 | 0.9% | $542.96m | |
| BIIB | Biogen Inc. | 0.63% | 286.21 | 1.2% | $478.24m | |
| REGN | Regeneron Pharmaceuticals, Inc. | -0.30% | 293.74 | 2.6% | $304.78m | |
| VRTX | Vertex Pharmaceuticals Incorporated | 0.34% | 157.50 | 1.9% | $219.69m | |
| ALXN | Alexion Pharmaceuticals, Inc. | 0.51% | 117.74 | 2.0% | $210.05m | |
| ILMN | Illumina, Inc. | -1.70% | 266.22 | 3.5% | $198.41m | |
| A | Agilent Technologies, Inc. | -1.50% | 63.16 | 1.5% | $196.40m | |
| NKTR | Nektar Therapeutics | -0.77% | 79.96 | 6.0% | $184.19m | |
| INCY | Incyte Corporation | 2.64% | 68.43 | 2.5% | $149.75m | |
| BMRN | BioMarin Pharmaceutical Inc. | 4.77% | 92.49 | 4.4% | $135.47m | |
| SRPT | Sarepta Therapeutics, Inc. | 1.85% | 91.65 | 16.6% | $126.22m | |
| BLUE | Bluebird Bio, Inc. | 0.62% | 188.15 | 15.7% | $98.65m | |
| EXAS | Exact Sciences Corporation | -1.95% | 51.82 | 25.5% | $98.64m |
Company Profile
Nektar Therapeutics is a clinical-stage biopharmaceutical company, which engages in developing drug candidates that utilize its PEGylation and polymer conjugate technology platforms. Its products contain drug candidates of therapeutic areas, including oncology, pain, anti-infectives, anti-viral, and immunology. The company provides small molecule drugs, peptides and other potential biologic drug candidates. It's drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient. Nektar Therapeutics was founded in 1990 and is headquartered in San Francisco, CA.